These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33509695)

  • 1. Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States.
    Net P; Colrat F; Nascimento Costa M; Bianic F; Thommes E; Alvarez FP
    Vaccine; 2021 Mar; 39 Suppl 1():A56-A69. PubMed ID: 33509695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.
    Mattock R; Gibbons I; Moss J; Mealing S; Largeron N; Carroll S; Alvarez FP
    J Med Econ; 2021; 24(1):1261-1271. PubMed ID: 34726129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
    PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
    Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
    Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season.
    Pelton SI; Divino V; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G; Postma MJ
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Nguyen VH; Vizzotti C; Uruena A; Giglio N; Magneres C; Richmond H
    Vaccine; 2020 Apr; 38(20):3682-3689. PubMed ID: 32249017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Gärtner BC; Weinke T; Wahle K; Kwetkat A; Beier D; Schmidt KJ; Schwarz TF
    Vaccine; 2022 May; 40(22):2999-3008. PubMed ID: 35459556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
    Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
    Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
    Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Redondo E; Drago G; López-Belmonte JL; Guillén JM; Bricout H; Alvarez FP; Callejo D; Gil de Miguel Á
    Vaccine; 2021 Aug; 39(36):5138-5145. PubMed ID: 34344553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
    Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
    Amiche A; Tanriover MD; Bellier L; Ugur B; Akin L
    Value Health Reg Issues; 2021 Sep; 25():15-22. PubMed ID: 33485248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.